Koninklijke Philips N.V. (DE:PHIA)
NYSE:PHIA
PHIA Stock Chart & Stats
€24.00
€0.00(0.00%)
At close: 4:00 PM EDT
€24.00
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€18.90 - €27.60
Previous CloseN/A
Volume59.00
Average Volume (3M)35.00
Market Cap
€23.07B
Enterprise Value€28.38B
Total Cash (Recent Filing)€2.79B
Total Debt (Recent Filing)€8.09B
Price to Earnings (P/E)24.8
Beta0.81
Next Earnings
May 06, 2026EPS Estimate
0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.61
Shares Outstanding962,920,100
10 Day Avg. Volume17
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)2.02
Price to Sales (P/S)1.24
P/FCF Ratio24.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.52
Revenue Forecast (FY)€17.86B
Bulls Say, Bears Say
Bulls Say
Profitability RecoveryA return to positive earnings and improved gross and operating margins in 2025 suggests the company's turnaround actions are taking hold. Durable margin improvement increases free‑cash‑flow capacity, supports reinvestment in R&D and services, and helps rebuild returns on equity if sustained beyond one year.
Productivity And Cost SavingsMaterial, multi‑year productivity savings materially restructure the cost base and are a durable lever to protect margins against cyclical pressures and tariffs. Continued program delivery increases operating leverage, makes margins less sensitive to revenue swings, and supports sustainable cash generation.
Innovation And Strategic M&AA strong innovation pipeline and targeted M&A broaden product differentiation in high‑value hospital imaging and interventional spaces. New platforms and acquisitions enhance attachable software/services and consumables, supporting higher mix, stickier installed‑base revenue and durable competitive advantage.
Bears Say
Respironics Legal/regulatory RiskPersistent legal, regulatory and remediation obligations tied to Respironics create structural cash demands and extended oversight risk. Beyond one‑off settlements, consent decrees and investigations can limit new product approvals, increase compliance costs and weaken hospital procurement confidence over multiple years.
Tariff And Trade ExposureLarge, recurring tariff headwinds act as a structural margin tax on products sold into affected markets. While mitigations (pricing, localization) help, uncertain trade policy and ongoing tariff exposure materially compress margins unless fully offset by productivity or price increases.
Multi‑year Revenue And Cash VolatilityA history of flat revenues and episodic negative free cash flow undermines predictability and strategic flexibility. Volatile cash generation and some capital base erosion increase sensitivity to one‑off charges and make sustained investment, dividend policy and deleveraging harder without consistent top‑line recovery.
Koninklijke Philips News
PHIA FAQ
What was Koninklijke Philips N.V.’s price range in the past 12 months?
Koninklijke Philips N.V. lowest stock price was €18.90 and its highest was €27.60 in the past 12 months.
What is Koninklijke Philips N.V.’s market cap?
Koninklijke Philips N.V.’s market cap is €23.07B.
When is Koninklijke Philips N.V.’s upcoming earnings report date?
Koninklijke Philips N.V.’s upcoming earnings report date is May 06, 2026 which is in 23 days.
How were Koninklijke Philips N.V.’s earnings last quarter?
Koninklijke Philips N.V. released its earnings results on Feb 10, 2026. The company reported €0.61 earnings per share for the quarter, beating the consensus estimate of €0.482 by €0.128.
Is Koninklijke Philips N.V. overvalued?
According to Wall Street analysts Koninklijke Philips N.V.’s price is currently Overvalued.
Does Koninklijke Philips N.V. pay dividends?
Koninklijke Philips N.V. does not currently pay dividends.
What is Koninklijke Philips N.V.’s EPS estimate?
Koninklijke Philips N.V.’s EPS estimate is 0.2.
How many shares outstanding does Koninklijke Philips N.V. have?
Koninklijke Philips N.V. has 962,920,100 shares outstanding.
What happened to Koninklijke Philips N.V.’s price movement after its last earnings report?
Koninklijke Philips N.V. reported an EPS of €0.61 in its last earnings report, beating expectations of €0.482. Following the earnings report the stock price went up 13.115%.
Which hedge fund is a major shareholder of Koninklijke Philips N.V.?
Currently, no hedge funds are holding shares in DE:PHIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Koninklijke Philips Stock Smart Score
Company Description
Koninklijke Philips N.V.
Koninklijke Philips N.V. operates as a health technology company in North America and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, computed tomography (CT) systems, X-ray systems, and detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; integrated interventional systems; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding and digital parental solutions; and male grooming and beauty products and solutions. It has a strategic collaboration with Ibex Medical Analytics Ltd. to jointly promote the digital pathology and AI solutions to hospitals, health networks, and pathology laboratories worldwide, as well as a strategic partnership agreement with NICO.LAB. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
PHIA Company Deck
PHIA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a broadly positive operational and financial performance: strong Q4 order intake and sales acceleration, substantial margin expansion, robust Personal Health and Connected Care momentum, significant productivity delivered and an active innovation pipeline. These positives are balanced by tangible near‑term headwinds — notably tariffs (annualized impact in 2026), ongoing Respironics‑related legal and regulatory matters, China tender dynamics, and some D&T margin pressure and Q1 phasing risk. Management has mitigations in place (productivity programs, pricing, localization) and a clear guide for 2026 (3%–4.5% sales growth; 12.5%–13% EBITDA margin), which supports confidence in execution despite the known risks.View all DE:PHIA earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---